12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Dyax, Lee's Pharmaceutical deal

Dyax granted Lee's CVie Therapeutics subsidiary exclusive rights to develop and commercialize Kalbitor ecallantide to treat hereditary angioedema (HAE) and other angioedema indications in China. Dyax...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >